Taiwan COVID vaccine maker says it had wanted to do stage 3 trials
06/03/2021 11:13 PM
CNA file photo
Taipei, June 3 (CNA) United Biomedical, a Taiwan biopharmaceutical firm developing COVID-19 vaccines, on Thursday said it had initially planned on following international norm and entering phase 3 clinical trials before seeking government approval for its COVID-19 vaccine.
In response to public concerns that United Biomedical s vaccines could be launched without going through phase-three clinical trials, the company s Chief Operating Officer (COO) Peng Wen-jiun (彭文君) said at a forum that the company had initially planned on following through the international norm, but Taiwan s Center for Drug Evaluation (CDE) and Food and Drug Administration (FDA) suggested that the company increase the number of participants to a larger-than-normal scale in the second phase of clinical trials instead.
Taipei, June 3 (CNA) A total of 180 people have contracted the coronavirus in cluster infections at 60 long-term care facilities in Taiwan since mid-May, when community transmission broke out in Taiwan, according to the Central Epidemic Command Center (CECC).
The Central Epidemic Command Center (CECC) yesterday reported 364 new domestic cases of COVID-19, 219 backlogged cases and 17 deaths, while more than 1 million vaccine doses donated by Japan are to arrive today.
Last week, Japan announced a plan to share vaccines with Taiwan and today, 1.24 million doses of the AstraZeneca vaccine are to arrive in Taiwan, the Chinese-language Liberty Times (sister paper of the Taipei Times) reported yesterday, citing a report by Japanese public broadcaster NHK and an anonymous source in Tokyo.
Of the new local cases, 186 are male and 178 female, aged under five to over 90,